Last reviewed · How we verify
HyperCVAD
HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption.
HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption. Used for Acute lymphoblastic leukemia (ALL), Lymphoma, Chronic myeloid leukemia (CML) in blast phase.
At a glance
| Generic name | HyperCVAD |
|---|---|
| Sponsor | Amgen |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HyperCVAD is an intensive combination chemotherapy regimen consisting of cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternated with high-dose methotrexate and cytarabine. These agents work through multiple mechanisms including alkylation, microtubule disruption, and antimetabolite activity to induce apoptosis in malignant cells. The regimen is designed for hematologic malignancies where intensive multi-agent chemotherapy provides superior outcomes.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Lymphoma
- Chronic myeloid leukemia (CML) in blast phase
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Cardiotoxicity (from doxorubicin)
- Neurotoxicity (from vincristine)
- Infection
Key clinical trials
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia (PHASE3)
- Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (PHASE3)
- A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (EARLY_PHASE1)
- BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. (PHASE2)
- RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. (PHASE2)
- Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyperCVAD CI brief — competitive landscape report
- HyperCVAD updates RSS · CI watch RSS
- Amgen portfolio CI